Skip to content

Ketamine: all studies

Page 261 of 448: studies 2,601 to 2,610 of 4,475, newest first. Back to the ketamine overview

Research

Pharmacological fMRI: Effects of subanesthetic ketamine on resting-state functional connectivity in the default mode network, salience network, dorsal attention network and executive control network

NeuroImage: Clinical 2018 Felix Mueller, Francesco Musso, Markus K. London et al. 65 citations

Background: Subanesthetic dosages of the NMDAR antagonist, S-Ketamine, can cause changes in behavior in healthy subjects, which are similar to the state acute psychosis and are relevant in translational schizophrenia research. Functional magnetic resonance imaging (fMRI) can be used for non-hypothesis-driven analysis of brain connectivity. The correlation between clinical behavioral scores and...

Back to the Future: Ketamine and Nitrous Oxide in Major Refractory Depression

December 28, 2017 V. Whizar-Lugo, Cesar Heredia-Mota, R. Camacho

Major depression (MD) is a very common chronic mental illness that causes substantial disability in millions of adolescents and adults throughout the world. In the United States of North America there is an annual risk of depression of 6.6%. Unfortunately, only 30-40% of patients will remit with the usual antidepressant drugs and there is a high risk of suicide attempts during the first month...

A Case Report of A Patient with Treatment-Resistant Depression Successfully Treated with Repeated Intravenous Injections of A Low Dosage of Ketamine.

Shanghai archives of psychiatry December 25, 2017 Shikai Wang, Mincai Qian, Liang Li et al.

Depression is a highly prevalent and severely disabling disease. The treatment effects, intensity and onset time of antidepressants have been highlighted in many studies. Recent studies on the rapid-onset of antidepressant response focused on the effect of a single low dose of intravenous ketamine. However, there are still some problems with treatment, including safety, efficacy, ethics, dose,...

Is Metabolism of (R)-Ketamine Essential for the Antidepressant Effects?

The International Journal of Neuropsychopharmacology December 23, 2017 Shigeyuki Chaki 17 citations

Major depressive disorder (MDD) affects approximately 10% to 20% of the US population (Kessler et al. , 2005); thus, the economic burden of MDD is immense. Currently, selective serotonin reuptake inhibitors and serotonin- and noradrenaline-reuptake inhibitors are widely prescribed for patients with MDD as first-line treatments. However, these medications have several drawbacks; approximately...

Role of 5-HT1A Receptor Stimulation in the Medial Prefrontal Cortex in the Sustained Antidepressant Effects of Ketamine

The International Journal of Neuropsychopharmacology December 22, 2017 K. Fukumoto, M. Iijima, Takeo Funakoshi et al.

Abstract Background We previously reported that serotonergic transmission plays an important role in antidepressant effects of ketamine. However, detailed mechanisms have not been elucidated. Among the serotonin receptor subtypes, the serotonin1A receptor in the medial prefrontal cortex has an important role in depression. Here, we investigated the role of the medial prefrontal cortex...

Effects of short term low dose melatonin and ketamine on depressive behavior and BDNF expression in rats with chronic stress depression

Zhonghua xingwei yixue yu naokexue zazhi December 20, 2017 Haonan Li, Hongwei Sun, Yanyu Wang et al.

Objective To evaluate the antidepressant action of melatonin in stress model of depression and the effects of the melatonin on depressive-like behavior. Methods Forty male Wistar rats were randomly divided into four groups(n=10): controls group (CON), chronic unpredictable mild stress group(CUS), chronic unpredictable mild stress group + melatonin group(CUS+ MT) and chronic unpredictable mild...

DOI: 10.3760/cma.j.issn.1674-6554.2017.12.003 (opens in new tab) Behavioural despair test Melatonin Chronic stress Endocrinology +5

Possible role of the gut microbiota–brain axis in the antidepressant effects of (R)-ketamine in a social defeat stress model

Translational Psychiatry December 15, 2017 Chun Yang, Youge Qu, Yuko Fujita et al. 231 citations

Accumulating evidence suggests that the gut microbiota-brain axis plays a role in the pathogenesis of depression, thereby contributing to the antidepressant actions of certain compounds. (R)-ketamine has a greater potency and longer-lasting antidepressant effects than (S)-ketamine. Here, we investigated whether the gut microbiota plays a role in the antidepressant effects of these two ketamine...

Ketamine for rapid reduction of suicidal thoughts in major depression: a midazolam-controlled randomized clinical trial

American Journal of Psychiatry December 5, 2017 Michael F Grunebaum, Hanga C Galfalvy, Tse-Hwei Choo et al. 428 citations

Objective Pharmacotherapy to rapidly relieve suicidal ideation in depression may reduce suicide risk. Rapid reduction in suicidal thoughts after ketamine treatment has mostly been studied in patients with low levels of suicidal ideation. Method This randomized clinical trial tested the effect of adjunctive sub-anesthetic intravenous ketamine on clinically significant suicidal ideation in major...

Effects of sodium nitroprusside in the prevention of schizophrenia-like symptoms induced by ketamine – A translational double-blind study

December 1, 2017 Tatiana M N Rezende, J. P. Maia-De-Oliveira, Ludmyla Kandratavicius et al.

Background: Recent evidence has shown improvements in schizophrenia symptoms after the infusion of sodium nitroprusside (SNP), a nitric oxide (NO) donor. In the rat model of schizophrenia using ketamine injection, pretreatment with SNP seems to prevent behavioral changes associated with positive symptoms for up to one week. Objective: We investigated whether SNP would have preventative effects...

Dose-Related Effects of Adjunctive Ketamine in Taiwanese Patients with Treatment-Resistant Depression.

Neuropsychopharmacology December 2017 Tung-Ping Su, Mu-Hong Chen, Cheng-Ta Li et al.

The antidepressant effects of ketamine are thought to depend on brain-derived neurotrophic factor (BDNF) genotype and dose. The purpose of this study was to characterize the dose-related antidepressant effects of ketamine in patients with treatment-resistant depression drawn from a Chinese population predominately possessing lower activity BDNF genotypes (Val/Met, Met/Met). We conducted a...